SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Issuer
PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the Month of February, 2004
Commission File Number 0-30860
Axcan Pharma Inc.
-----------------
(Exact Name of Registrant)
597, boul. Laurier, Mont-Saint-Hilaire (Quebec), Canada J3H 6C4
---------------------------------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
X
--------- ---------
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also hereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No
X
--- ---
This Form 6-K consists of: A press release issued by Axcan Pharma Inc. on
February 5, 2004, entitled "Axcan Reports Strong First Quarter 2004 Results
Revenue up 52% to $57.6 Million."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AXCAN PHARMA INC.
Date: February 10, 2004 By: /s/ Jean Vezina
------------------
Name: Jean Vezina
Title: Vice-President, Finance and
Chief Financial Officer